The Special Access Programme (SAP) provides access to nonmarketed drugs for practitioners treating patients with serious or life-threatening conditions when conventional therapies have failed, are unsuitable, or unavailable. The SAP authorizes a manufacturer to sell a drug that cannot otherwise be sold or distributed in Canada. Drugs considered for release by the SAP include pharmaceutical, biologic, and radio-pharmaceutical products not approved for sale in Canada.
Canadians with porphyria can access two treatments through the SAP - Normosang or Panhematin for Hepatic porphyria - Acute Intermittent Porphyria, Variegate Porphyria and Hereditary Coproporphyria; and Scenesse for Erythropoietic Protoporphyria.
Information on the Special Access Program (SAP):
Source: Health Canada
Last Updated: 10/January/2017